Please assess the completion status of the following clinical trial:

Trial Title: P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, ≥18 years of age~* Must have a confirmed diagnosis of active MM~* Must have measurable MM~* Must have relapsed / refractory MM, having received treatment with proteasome inhibitor and IMiD \[Phase 2: Must have relapsed / refractory MM, and refractory to last line of therapy, having received treatment with proteasome inhibitor, an IMiD, CD38 targeted therapy and undergone autologous stem cell transplant (ASCT) or not a candidate for ASCT.\]~* Must have adequate hepatic, renal, cardiac and hematopoietic function~Exclusion Criteria:~* Is pregnant or lactating~* Has inadequate venous access and/or contraindications to leukapheresis~* Has active hemolytic anemia, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, disseminated intravascular coagulation, leukostasis, amyloidosis, significant autoimmune, CNS or other malignant disease~* Has an active second malignancy (not disease-free for at least 5 years) in addition to MM, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma.~* Has active autoimmune disease~* Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy, etc.~* Has an active systemic infection~* Has hepatitis B or C virus, human immunodeficiency virus (HIV), or human T-lymphotropic virus (HTLV) infection, or any immunodeficiency syndrome.~* Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol~* Has receiving immunosuppressive or other contraindicated therapies within the excluded time frame from entry~* Has CNS metastases or symptomatic CNS involvement~* Has a history of having undergone allogeneic stem cell transplantation, or any other allogeneic or xenogeneic transplant, or has undergone autologous transplantation within 90 days.~* Unable to take acetylsalicylic acid (ASA) daily as prophylactic anticoagulation. (Cohorts R and RP only).~* History of thromboembolic disease within the past 6 months, regardless of anticoagulation (Cohorts R and RP only).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: P-BCMA-101 CAR-T cells (Type: EXPERIMENTAL): Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells. Rimiducid may be administered as indicated.
- Phase 1 P-BCMA-101 CAR-T cells (Cohort A) (Type: EXPERIMENTAL): Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
- Phase 1 P-BCMA-101 CAR-T cells (Cohort B) (Type: EXPERIMENTAL): Single dose given across three intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
- Phase 1 P-BCMA-101 CAR-T cells (Cohort C) (Type: EXPERIMENTAL): Single dose given across two intravenous infusions of CAR-T cells. Rimiducid may be administered as indicated.
- Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort R) (Type: EXPERIMENTAL): Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
- Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RP) (Type: EXPERIMENTAL): Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before apheresis. Rimiducid may be administered as indicated.
- Phase 1 P-BCMA-101 CAR-T cells with Comb.Therapy (Cohort RIT) (Type: EXPERIMENTAL): Single intravenous infusion of CAR-T cells, with combination therapy, beginning one week before CAR-T infusion. Rimiducid may be administered as indicated.
- Phase 2: P-BCMA-101 CAR-T Cells (Type: EXPERIMENTAL): CAR-T cells administered via intravenous infusion as a total dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility